Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic
Mark S Cragg, Elisa S Jansen, Michele Cook, Claire Harris, Andreas Strasser, Clare L Scott
J. Clin. Invest. | AMER SOC CLINICAL INVESTIGATION INC | Published : 2008
Awarded by National Health and Medical Research Council
Awarded by Leukemia and Lymphoma Society
Awarded by NIH
Awarded by NATIONAL CANCER INSTITUTE
We are grateful to G. Boyle, P. Hersey, and J. Blaydes for the kind gift of cell lines, J. Baell for ABT-737, and R. Anderson for antibodits. We thank all of our colleagues in the Molecular Genetics of Cancer Division and Cancer Sciences Division of Southampton University for gifts of reagents, scientific advice, and technical support. This work was supported by the National Health and Medical Research Council (NHMRC; program no. 257502; RD Wright Biomedical CDA 40667S), by a grant from the Leukemia and Lymphoma Society (SCOR grant no. 7015), by National Cancer Institure, NIH, grants CA 80188 and CA 43540, and by a Leukemia Research UK fellowship (to M.S. Cragg).